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Background: Despite improved secondary prevention efforts, acute coronary syndrome (ACS) recurrence
among patients with prior history of coronary events remains high. The differences in presentation,
management, and subsequent clinical outcomes in patients with and without a prior myocardial infarction
(MI) and presenting with another episode of ACS remain unexplored.
Methods: A total of 3,624 consecutive patients admitted to the University of Michigan with ACS
from January 1999 to June 2006 were studied retrospectively. In-hospital management, outcomes, and
postdischarge outcomes such as death, stroke, and reinfarction in patients with and without a prior MI were
compared.
Results: Patients with a prior MI were more likely to be older and have a higher incidence of diabetes
mellitus, hypertension, hyperlipidemia, and peripheral vascular disease. In-hospital outcomes were not
significantly different in the 2 groups, except for a higher incidence of cardiac arrest (4.3% versus 2.5%,
p<0.01) and cardiogenic shock (5.7% versus 3.9%, p= 0.01) among patients without a prior MI. However,
at 6 mo postdischarge, the incidences of death (8.0% versus 4.5%, p<0.0001) and recurrent MI (10.0%
versus 5.1%, p<0.0001) were significantly higher in patients with a prior history of MI compared with those
without.
Conclusion: Patients with prior MI with recurrent ACS remain at a higher risk of major adverse events on
follow-up. This may be partly explained by the patients not being on optimal medications at presentation,
as well as disease progression. Increased efforts must be directed at prevention of recurrent ACS, as well as
further risk stratification of these patients to improve their overall outcomes.
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Introduction
Patients who present with an acute coronary syndrome
(ACS) continue to represent a major health concern. Sec-
ondary prevention measures improve long-term morbidity
and mortality after an initial acute myocardial infarction
(MI). As a result, more than 1 million individuals survive an
MI annually in the US. Despite our best efforts at secondary
prevention, the rate of ACS recurrence in this group remains
relatively high. It is well-known that these patients with a
recurrent ACS have worse outcomes; however, the timing of
these adverse outcomes, as well as the contributing factors,
remain unexplored. In this study, we sought to compare
the differences in the presenting characteristics, in-hospital
management, and subsequent clinical outcomes of patients
with and without a prior MI and presenting with an ACS.
Methods
The study cohort comprised of 3,624 consecutive patients
who presented between January 1999 and June 2006 and
were admitted to the University of Michigan Medical Cen-
ter (Ann Arbor, Mich., USA) with a diagnosis of acute
coronary syndrome (ACS). All patients were initially iden-
tified by a discharge diagnosis of unstable angina (UA),
ST-segment elevation myocardial infarction (STEMI), or
non-ST-segment elevation myocardial infarction (NSTEMI).
Identified charts were reviewed by nurses or physicians
for entry criteria. Inclusion into the study required symp-
toms consistent with acute coronary insufficiency, along
with 1 or more of the following: a documented history
of coronary artery disease; electrocardiographic changes
suggestive of ischemia, such as transient ST-segment ele-
vations of ≥1 mm, ST-segment depressions of ≥1 mm, new
T-wave inversions of ≥1 mm, pseudonormalization of previ-
ously inverted T-waves, new Q-waves, new R-wave >S-wave
in lead V1, or a new left bundle branch block [CK] evi-
dence of coronary artery disease by cardiac catheterization;
and/or elevated cardiac biomarkers (creatin kinase-[CK]-
MB >2 times the upper limit of normal and/or troponin
I >0.39 ng/ml). Clinical, demographic, treatment, and out-
come data were abstracted from medical charts by trained
abstractors (physicians and/or cardiology research nurses).
Data were collected on a 6-page form and then forwarded
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abstractors (physicians and/or cardiology research nurses).
Data were collected on a 6-page form and then forwarded
to a database service for dual data entry after review for
face validity. Demographic variables included age and sex.
Comorbidities included prior history of heart disease includ-
ing angina, congestive heart failure (CHF), myocardial
infarction (MI), coronary artery bypass grafting (CABG),
percutaneous coronary intervention (PCI), diabetes mel-
litus (DM), smoking, hyperlipidemia, and hypertension.
Electrocardiogram (ECG) changes and initial laboratory
data were recorded. Procedures and complications during
the ACS hospitalization were documented. These patients
were then followed-up by telephone 6 mo after their dis-
charge, at which point outcomes and medication adherence
were noted. The protocol was approved by the institutional
review board at the University of Michigan and informed
consent was obtained from all patients.
Patients were divided into 2 groups: Group 1 (n = 1,508)
had a prior documented MI by history (either STEMI or
NSTEMI) and Group 2 (n = 2,116) had no prior documented
history of MI. Univariate comparisons between the 2 groups
were performed using Pearson’s chi-square test and Fisher’s
exact test for categorical variables, and a Student t test for
continuous variables. Multivariable logistic regression mod-
eling was performed to derive the independent association of
clinical outcomes at 6 mo postdischarge with a prior history
of MI. We compared in-hospital outcomes including death,
reinfarction, stroke, cardiogenic shock, pulmonary edema,
cardiac arrest, atrial fibrillation/flutter, and the composite
of major adverse cardiac events (MACE) (i.e., death, stroke,
and reinfarction). Reinfarction was defined as re-elevation
of CK-MB to above the upper limits of normal and increased
by at least 50% over the previous value. Stroke, either
embolic and/or hemorrhagic, was defined as the onset of
focal neurological signs or symptoms; for example, loss or
slurring of speech, with confirmation by either computed
tomography or magnetic resonance imaging. Cardiogenic
shock was defined as the presence of pulmonary edema
and hypoperfusion characterized by systolic blood pressure
<80 mm Hg. We also compared rates of death, recurrent
MI, unscheduled revascularization, stroke, and a composite
of these at 6 mo postdischarge. Statistical Analysis Software
(SAS) 8.2 (SAS Institute, Cary, NC, USA) was used for all
analyses.
Results
This study included 3,624 patients, 1,508 patients with a
prior MI and 2,116 without, who presented with an ACS.
As shown in Table 1, patients with a prior history of MI
were older and (mean age: 65.3 y versus 62.3 y, p<0.0001),
and had a higher incidence of DM (37.5% versus 26.1%,
p<0.0001), hypertension (79.5% versus 62.8%, p<0.0001),
hyperlipidemia (77.1% versus 53.2%, p<0.0001), peripheral
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Figure 1: Chronic medications.
cardiovascular history. These patients had lower systolic
blood pressures (138±29 versus 142±31 mm Hg, p<0.001)
and lower initial serum low-density lipoprotein (LDL)
cholesterol levels (90±37 versus 109±42 mg/dl, p<0.0001)
than those without (Table 1). As one would expect, patients
with a prior MI were more frequently on chronic β-blockers,
angiotensin-converting enzyme (ACE) inhibitors, statins,
and aspirin than those without at presentation with recurrent
ACS (Figure 1). These patients were more likely to present
in Killip class II heart failure (13.5% versus 7.9%, p<0.0001),
and were generally a higher risk group based on their
average risk scores during hospitalization (Table 1).
Although the in-hospital usage of statins was higher
in this higher risk group (76.2% versus 71.6%, p<0.01),
the use of thienopyridines (54.9% versus 60.9%, p<0.001),
antithrombotics (86.9% versus 89.5%, p = 0.01), and glyco-
protein IIb/IIIa inhibitors (20.0% versus 32.0%, p<0.0001)
was significantly less. Also, the use of coronary revascu-
larization procedures was significantly less in ACS patients
with a prior MI (Table 2).
In-hospital adverse clinical events were not significantly
different in the 2 groups, except for the incidence of cardiac
arrest, which was higher in patients without a prior history of
MI (4.3% versus 2.5%, p<0.01) (Table 3). Moreover, patients
in this group were more likely to develop cardiogenic shock
(5.7% versus 3.9%, p = 0.01), and were more likely to require
the use of pulmonary artery (PA) catheters (10.3% versus
6.9%, p<0.001) and intra-aortic balloon pumps (IABP) (6.2%
versus 4.0%, p<0.01). However, at 6 mo postdischarge,
the unadjusted rates of death, recurrent MI, stroke, and
unscheduled revascularization were significantly higher in
patients with a prior history of MI compared with those
without (Table 4). Multivariate logistic regression analysis
showed that a history of prior MI remained a significant
independent risk factor for MACE at 6 mo postdischarge
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Clinical Investigations continued





n= 2,116 (58.4%) p-value
Age (mean SD) 65 (14) 62 (13) <0.0001
Male, sex 533 (35.3) 748 (35) 0.5
Body mass index (kg/m2) (mean SD)∗ 29.3 (8.9) 29.6 (11.3) 0.4
Cardiovascular History
Angina 852 (56.8) 769 (36.4) <0.0001
Transient ischemic attack/stroke 230 (15.3) 164 (7.8) <0.0001
Congestive heart failure 489 (32.6) 204 (9.6) <0.0001
Percutaneous intervention 758 (50.4) 272 (12.9) <0.0001
CABG surgery 554 (36.9) 228 (10.8) <0.0001
Risk Factors
Smoking history 957 (63.5) 1257 (59.6) 0.02
Diabetes mellitus 564 (37.5) 552 (26.1) <0.0001
Hypertension 1,192 (79.5) 1,327 (62.8) <0.0001
Hyperlipidemia 1,159 (77.1) 1,122 (53.2) <0.0001
Peripheral vascular disease 290 (19.3) 210 (10) <0.0001
Systolic blood pressure (mean SD, mm Hg) 138 (29) 142 (31) <0.001
Initial serum LDL cholesterol (mean SD, mg/dl) 90 (37) 109 (42) <0.0001
Fasting serum glucose (mean SD mg/dl) 123±61 116±44 0.01
LVEF % (mean SD) 47 (17) 53 (14) <0.0001
Presentation diagnosis
Unstable angina 468 (31) 375 (17.7) <0.0001
Non-ST-elevation myocardial infarction 870 (57.7) 1,174 (55.5) 0.2
ST-segment elevation myocardial infarction 170 (11.3) 567 (26.8) <0.0001
Mean GRACE score (SD) 118 (36) 93 (34) <0.0001
∗Body mass index was calculated as weight in kilograms divided by the square of height in meters. Abbreviations: CABG= coronary artery bypass graft;
GRAC = global registry of acute coronary events;11 LVEF= left ventricular ejection fraction; MI=myocardial infarction; SD= standard deviation.
after adjusting for age, gender, and the presence or absence
of DM, hypertension, hyperlipidemia, peripheral vascular
disease, CHF, renal insufficiency, angina history, stroke,
ejection fraction (EF) at presentation, renal insufficiency,
and in-hospital therapies with an odds ratio (OR) of 1.41
(95% confidence interval [CI]: 1.029–1.94; p< 0.05).
Discussion
The principal findings of our study are 3-fold. First, the
patients with a prior history of MI represented a significant
portion of all patients (approximately 40%) presenting with
an ACS and were clearly at higher risk in terms of
comorbid conditions. Patients in this group were more
likely to be on aspirin, β-blockers, statins, and ACE
inhibitors upon presentation and were more likely to receive
statins during their hospitalization. However, the use of
in-hospital thienopyridines, antithrombotics, glycoprotein
IIb/IIIa inhibitors, and coronary revascularization was
significantly less in this group. Second, in spite of worse
comorbidities, the in-hospital outcomes in this group were
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n= 2,116 (58.4%) p-value
Aspirin 1,455 (96.5) 2,038 (96.3) NS
β-blockers 1,374 (91.1) 1,939 (91.6) NS
ACE inhibitor 1,001 (66.4) 1,417 (67.0) NS
Statins 1,149 (76.2) 1,515 (71.6) 0.002
Thienopyridines 828 (54.9) 1,288 (60.9) <0.001
Unfractionated heparin/LMWH 1,310 (86.9) 1,894 (89.5) 0.01
Glycoprotein IIb/IIIa inhibitor 303 (20.1) 677 (32.0) <0.0001
Thrombolytics 39 (2.6) 152 (7.2) <0.0001
Percutaneous coronary intervention 526 (34.9) 1,090 (51.5) <0.0001
Coronary artery bypass grafting 91 (6.0) 243 (11.5) <0.0001
Abbreviations: ACE = angiotensin-converting enzyme; LMWH= low molecular weight heparin; MI = myocardial infarction.





n= 1,781 (%) p-value
Death 49 (3.2) 90 (4.3) 0.12
Cardiac arrest 38 (2.5) 91 (4.3) 0.004
CHF/Pulmonary edema 133 (8.8) 209 (9.9) 0.29
Cardiogenic shock 59 (3.9) 121 (5.7) 0.01
Atrial fibrillation/flutter 91 (6.1) 154 (7.3) 0.15
Sustained VF/VT 45 (3.0) 87 (4.1) 0.07
AV block 14 (0.9) 29 (1.4) 0.22
MI/Reinfarction 79 (5.3) 101 (4.8) 0.52
Stroke 8 (0.5) 20 (0.9) 0.16
Major bleeding 90 (6.0) 116 (5.5) 0.53
MACE 127 (8.4) 192 (9.1) 0.5
Abbreviations: AV= atrio-ventricular; CHF= congestive heart failure; MACE=major acute coronary events; MI=myocardial infarction; VF= ventricular
fibrillation; VT= ventricular tachycardia.
similar to those without a prior MI. Third, patients in this
group were more likely to be discharged on statins and
were more likely to adhere to their ACE inhibitors 6 mo
postdischarge. Nevertheless, the rates of death, recurrent
MI, and MACE at 6 mo postdischarge remained significantly
higher in this group.
As expected, patients with a prior history of MI had
higher rates of cardiovascular risk factors and were more
likely to be on medications for these at the time of their
hospital presentation (Table 1, Figure 1). Encouragingly,
they had more favorable systolic blood pressures and lipid
profiles during their recurrent ACS presentation. However,
patients in this group had higher levels of fasting blood
glucose levels and lower left ventricular EFs at presenta-
tion. There were no significant differences in the use of
in-hospital aspirin, β-blockers, or ACE inhibitors among
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Clinical Investigations continued





n= 2,116 (58.4%) p-value
1 mo after discharge
Death 28 (2.1%) 30 (1.7%) 0.32
6 mo after discharge
Death 105 (8.0%) 81 (4.5%) <0.0001
MI 91 (10.0%) 66 (5.1%) <0.0001
Stroke 13 (1.2%) 18 (1.1%) 0.89
Unscheduled revascularization 80 (7.7%) 101 (6.8%) 0.38
MACE 199 (15.0%) 158 (8.6%) <0.0001
Abbreviations: MACE = major adverse cardiac event; MI = myocardial infarction.
the 2 groups. However, the use of in-hospital thienopy-
ridines, glycoprotein IIb/IIIa inhibitors, antithrombotics,
and coronary revascularization was significantly less in
patients with a prior MI. While this may be attributed
to differences in their hospital presentation, observations
from the Can Rapid Risk Stratification of Unstable Angina
Patients Suppress Adverse Outcomes with Early Imple-
mentation (CRUSADE) registry suggest that the use of
guideline-based acute recommendations and invasive car-
diac procedures is lower in higher risk presenters with
non-ST-elevation ACS.1
Interestingly, this group of patients, which was clearly
at a higher risk, did not have worse in-hospital outcomes
during their recurrent ACS episode. Moreover, the rates
of postdischarge death did not differ significantly between
the 2 groups, even in the immediate postdischarge period
(Table 4, Figure 4). While this may be due to our analysis
being underpowered to detect this difference, this finding
is consistent with a previous report by the Platelet Glyco-
protein IIb/IIIa in Unstable Angina: Receptor Suppression
Using Integrilin Therapy (PURSUIT) trial investigators who
showed that the history of prior MI does not appear to affect
outcomes in ACS for up to 1 mo after hospital discharge.2
In-hospital and short-term outcomes in ACS have been
previously shown to be determined less by the patient’s
risk factors and chronic medication use, and more by the
clinical features of their presentation, such as Killip class,
age, blood pressure, heart rate, elevations in biomarkers,
creatinine level, ST-segment deviation, heart rate, and the
resulting immediate therapies provided to them.3,4,5 How-
ever, at 6 mo postdischarge, patients with a prior history
of an MI who presented with a recurrent ACS were clearly
more likely to experience death and recurrent MI than
those without a prior MI. Rates of MACE at 6 mo remained
higher in this group, even after a multivariate adjustment
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Figure 2: Discharge medications.
increased number of patients in this higher risk group being
discharged on statins (Figure 2), and adhering to their ACE
inhibitors and β-blockers at 6 mo postdischarge (Figure 2).
A lower left ventricular EF in this group, as previously estab-
lished, remained an independent predictor of worse 6 mo
outcomes in the prior MI group.6,7,8 However, the history
of a prior MI predicted worse 6 mo outcomes even after
adjusting for EF.
Interestingly, patients with no prior coronary artery
disease (but no prior MI) had better follow-up survival as
compared with those with prior MI in spite of no in-hospital
differences in the use of aspirin, statins, β-blockers, and ACE
inhibitors during their ACS. We suspect that the explanation
for our findings include both a greater burden of coronary
artery disease and greater progression, despite increased
efforts at secondary prevention by the physician as well as
patients. However, in our study many patients who had a
prior MI did not appear to be on optimal medical therapy
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Figure 4: Unadjusted postdischarge survival. Abbreviation: CAD =
coronary artery disease.
(aspirin, statins, β-blockers, and ACE inhibitors) at the time
of presentation with their recurrent ACS (Figure 1). This
may explain part of the reason so many of these patients
present with a recurrent ACS. Additionally, these higher
risk patients were less likely to receive antithrombotic
or antiplatelet agents during their hospitalization. This
did not seem to be responsible for their worse follow-
up outcomes on multivariate analysis. However, coronary
revascularization procedures (PCI and CABG) were also
significantly underused in this group and this seems to be
partly responsible for their worse outcomes at 6 mo. We
speculate that the subsequent additive loss of myocardium
in a heart that is already previously damaged may be the
reason why these patients did poorly upon discharge.
Certainly, greater emphasis must be placed on long-term
prevention of a recurrent ACS by ensuring timely initiation
and subsequent adherence to optimal lifestyle and evidence-
based pharmacologic therapies after the first MI. Recent
studies have shown that risk stratification after ACS remains
suboptimal, regardless of presenting characteristics.9,10
Perhaps identification of higher risk patients with recurrent
ACS and implementation of in-hospital guideline-based care,
as well as multifaceted postdischarge interventions, may
improve their long-term outcomes.
Limitations
Our study should be interpreted in the context of several
limitations. The study was retrospective and lacked data
on the type, management, and timing of the previous MI.
Further, because of the small sample size we were unable
to adjust for other comorbid conditions, such as anemia,
chronic liver diseases, and pulmonary diseases, which
may have influenced mortality in our study population.
Moreover, other secondary prevention measures, such
as diet, exercise, and smoking cessation, could not be
compared in our database and may be partly responsible for
this difference. The results of our study should therefore
be interpreted as generating a hypothesis, and needs to be
confirmed in larger registries and with clinical trials.
Conclusion
Our data reflect that patients with previous MI represent
approximately 40% of those coming into our medical
center with an ACS. These patients have similar in-hospital
outcomes as those presenting without a prior MI history,
but have substantially higher rates of recurrent events by
6 mo. Increased efforts must be directed at prevention of
recurrent ACS, and better risk stratification and long-term
medical management with more intense follow-up of these
patients may improve their overall outcomes.
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